AdvanCell Closes A$18M Series B Funding Led by Morningside
14.9.2022 17:16:00 EEST | Business Wire | Press release
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”
Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.
AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.
Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”
Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.
Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”
About AdvanCell
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au
About Morningside
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005846/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Brings Onchain Lending into Everyday Payments8.9.2026 15:00:00 EEST | Press release
Today, Visa (NYSE: V) announced a new approach to onchain credit designed to help stablecoin-linked card programs and fintechs access working capital using onchain lending infrastructure and Visa data. Onchain lending has emerged as one of the fastest-growing segments of digital finance. According to the Visa Onchain Analytics Dashboard, since 2020, more than $694 billion in stablecoin-denominated loans have been sent through onchain lending protocols, creating a global credit market that operates 24/7. Yet much of that activity remains concentrated within crypto markets and hasn’t meaningfully supported the businesses and payment experiences people use every day. Visa is helping bridge that gap by combining VisaNet settlement data with onchain credit infrastructure. This information can help lenders better understand how a program is operating, making it easier to evaluate financing opportunities that fit their needs and extend capital to support their goals. "Stablecoins are not only
Samsung Electronics and ASML Expand Strategic Collaboration for Next-Generation Semiconductor Manufacturing8.9.2026 14:51:00 EEST | Press release
Samsung Electronics and ASML today announced an expansion of their long-standing strategic partnership, deepening collaboration on High NA EUV lithography and advanced semiconductor manufacturing technologies that will help drive the next generation of innovation in the AI era. Building on years of successful cooperation, the companies will work together to accelerate the development and deployment of technologies that support the increasing performance and efficiency requirements of advanced semiconductor manufacturing. Samsung will join the industry initiative to advance next-generation 12-inch photomask technology for future manufacturing. The semiconductor industry has relied on the 6-inch photomask format for decades. With High NA EUV, the transition to larger, 12-inch masks is expected to further increase fab productivity, lower chipmaking costs and remove stitching constraints. It will enable advanced chip manufacturers to fully leverage the advantages of High NA EUV, making fut
Hovione Appoints Stefan Doboczky as Chief Executive Officer8.9.2026 14:16:00 EEST | Press release
Hovione Holding AG today announced the appointment of Stefan Doboczky as Chief Executive Officer (CEO), effective April 1, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908358544/en/ Stefan Doboczky, Chief Executive Officer of Hovione. Photo credit: Karl Michalski. Stefan Doboczky has served as Chairman of the Board of Directors of Hovione Holding AG since 2024, where he has been instrumental in shaping the company’s strategy and vision. He will step down as Chairman on assuming the role of Chief Executive Officer. Founded in 1959, Hovione is a family-owned pharmaceutical technology and services group serving the industry worldwide, with more than 2,600 employees, four FDA-inspected production and R&D sites in Europe, the United States and China, and internationally recognized technology leadership in spray drying and continuous tableting. The appointment marks a return to the pharmaceutical industry for Stefan Dob
Hirect to Showcase In-House Developed 6,000 HP Electric Locomotive Propulsion System and Indian Railways Contract at InnoTrans 20268.9.2026 14:09:00 EEST | Press release
Hirect (NSE: HIRECT), a premier manufacturer of heavy-duty electrical and power electronic systems for rail network rolling stock, will debut its new 6,000 HP locomotive propulsion system at InnoTrans 2026, Berlin, 22 - 25 September. The company will also announce the first development order for the complete trainset propulsion system, which will deliver the power and traction package for Indian Railways' next-generation Mainline Electric Multiple Unit (MEMU) fleet. Hirect's 6,000 HP electric locomotive propulsion system — designed, engineered and manufactured entirely in-house, including its liquid-cooled IGBT traction inverters/converters and proprietary control software — completed its acceptance regime this year after successfully hauling loaded freight in a WAG-9 locomotive under India's severe duty cycles and demanding thermal operating environment. The qualification opens one of the world's largest locomotive markets to Hirect's complete propulsion package, and establishes a mod
NIQ Expands Product Intelligence Across Western Europe, Strengthening the Foundation for AI-Driven Commerce8.9.2026 13:32:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of NIQ Product Insights (NPI) across Western Europe, strengthening its Product Intelligence portfolio to help brands and retailers better understand what drives shopper choice and category growth. The expansion brings enhanced product intelligence capabilities to Austria, Belgium, Italy, Netherlands, Portugal, Spain and Switzerland, building on existing availability in France, Germany, Ireland, and the United Kingdom. As shoppers, and increasingly the digital and AI-powered tools that guide them, evaluate products against specific health, wellness, sustainability, and ingredient preferences, product attributes are becoming an increasingly important part of commerce’s intelligence infrastructure. Brands and retailers need more than traditional market measurement to understand which attributes influence selection and drives growth. NPI connects those attributes with real-world sales performance. NPI c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom